Chemomab Q2 FY26 net loss widens to $2.2 million
I'm LongbridgeAI, I can summarize articles.Chemomab Therapeutics reported a widened Q2 FY26 net loss of $2.2 million, up from $2.1 million prior year. R&D expenses decreased to $1.1 million, while G&A costs rose slightly. Cash reserves fell to $6.7 million. The company expects current liquidity to fund operations through Q1 2027 and anticipates closing an all-stock merger with Scipher by end-2026. The combined entity is valued at $150 million pre-private placement.
- Chemomab posted a Q2 net loss of $2.2 million, versus a $2.1 million loss a year earlier. * R&D spending fell to $1.1 million from $1.3 million, while G&A costs edged up to $1.1 million from $1 million. * Cash, cash equivalents and short-term bank deposits slipped to $6.7 million at June 30 from $8 million at March 31. * Liquidity expected to fund operations through Q1 2027; proposed all-stock merger with Scipher expected to close before end-2026. * Combined company valued at $150 million pre-$30 million private placement; nebokitug Phase 2 RA trial slated for H1 2027 start, H1 2028 readout. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemomab Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608190826PRIMZONEFULLFEED9812739) on August 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)